Результаты поиска - Javier Pinilla‐Ibarz

Отмена результатов
  1. 1
    Signaling Networks Associated with BCR–ABL–Dependent Transformation

    Signaling Networks Associated with BCR–ABL–Dependent Transformation по Lori Hazlehurst, Nadine N. Bewry, Rajesh R. Nair, Javier Pinilla‐Ibarz

    Опубликовано 2009
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  2. 2
    Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

    Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies по Jessica M. McDaniel, Javier Pinilla‐Ibarz, Pearlie K. Epling‐Burnette

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  3. 3
    Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia

    Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia по Wael Gamal, Melanie Mediavilla-Varela, Vishaal Kunta, Eva Sahakian, Javier Pinilla‐Ibarz

    Опубликовано 2025
    Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  4. 4
    Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance

    Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance по Nadine N. Bewry, Rajesh R. Nair, Michael F. Emmons, David Boulware, Javier Pinilla‐Ibarz, Lori A. Hazlehurst

    Опубликовано 2008
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  5. 5
    Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management

    Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management по Jorge E. Cortés, Carlos A. Jiménez, Michael J. Mauro, Alex Geyer, Javier Pinilla‐Ibarz, Benjamin D. Smith

    Опубликовано 2016
    Полный текст Полный текст
    Revisão
    Добавить в Избранное
    Сохранить в:
  6. 6
    <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides

    <scp>WT</scp>1 vaccination in <scp>AML</scp> and <scp>MDS</scp>: A pilot trial with synthetic analog peptides по Jason Brayer, Jeffrey E. Lancet, John J. Powers, Alan F. List, Lodovico Balducci, Rami S. Komrokji, Javier Pinilla‐Ibarz

    Опубликовано 2015
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  7. 7
    Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia

    Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia по Onyee Chan, Chetasi Talati, Leidy Isenalumhe, Samantha Shams, Lisa Nodzon, Michael G. Fradley, Kendra Sweet, Javier Pinilla‐Ibarz

    Опубликовано 2020
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  8. 8
    A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia

    A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia по Kathleen N. S. Cathcart, Javier Pinilla‐Ibarz, Tatyana Korontsvit, Joseph E. Schwartz, Victoriya Zakhaleva, Esperanza B. Papadopoulos, David A. Scheinberg

    Опубликовано 2003
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  9. 9
    Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells

    Peptide Epitopes from the Wilms' Tumor 1 Oncoprotein Stimulate CD4+ and CD8+ T Cells That Recognize and Kill Human Malignant Mesothelioma Tumor Cells по Rena J. May, Tao Dao, Javier Pinilla‐Ibarz, Tatyana Korontsvit, Victoriya Zakhaleva, Rong H. Zhang, P. Maslak, David A. Scheinberg

    Опубликовано 2007
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  10. 10
    Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

    Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance по Hagop M. Kantarjian, Phillipp le Coutre, Jorge E. Cortés, Javier Pinilla‐Ibarz, Arnon Nagler, Andreas Hochhaus, Shinya Kimura, Oliver G. Ottmann

    Опубликовано 2010
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  11. 11
    A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease

    A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease по Kendra Sweet, Lori Hazlehurst, Eva Sahakian, John J. Powers, Lisa Nodzon, Fadi Kayali, Kelly A. Hyland, Ashley Nelson, Javier Pinilla‐Ibarz

    Опубликовано 2018
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  12. 12
    Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of Real-World Patients with CLL

    Preliminary Results of Voice (Virtual Opinions poll Independent Centered on CLL patients’ Experience): A Global Survey to Assess the Disease-Specific Knowledge and Perspectives of... по Constantine S. Tam, Javier Pinilla Ibarz, Volkan Karakuş, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Nicolás Piotrowsky, Martin Šimkovič, Andrew Smith, Stephan Stilgenbauer

    Опубликовано 2022
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  13. 13
    Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival

    Inhibition of ER stress–associated IRE-1/XBP-1 pathway reduces leukemic cell survival по Chih-Hang Anthony Tang, Sujeewa Ranatunga, Crystina L. Kriss, Christopher L. Cubitt, Jianguo Tao, Javier Pinilla‐Ibarz, Juan R. Del Valle, Chih‐Chi Andrew Hu

    Опубликовано 2014
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  14. 14
    NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

    NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia по Susan O’Brien, Ellin Berman, Joseph O. Moore, Javier Pinilla‐Ibarz, Jerald P. Radich, Paul J. Shami, Benjamin D. Smith, David S. Snyder, Hema Sundar, Moshe Talpaz, Meir Wetzler

    Опубликовано 2011
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  15. 15
    The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance

    The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance по Alejandro Villagra, Fengdong Cheng, Hongwei Wang, Ildelfonso Suarez, Michelle Glozak, Michelle Maurin, Danny Nguyen, Kenneth L. Wright, Peter Atadja, Kapil N. Bhalla, Javier Pinilla‐Ibarz, Edward Seto, Eduardo M. Sotomayor

    Опубликовано 2008
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  16. 16
    Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison

    Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison по Kristin M. Phillips, Javier Pinilla‐Ibarz, Eduardo M. Sotomayor, Morgan Lee, Heather Jim, Brent J. Small, Lubomir Sokol, Jeffrey E. Lancet, Sara Tinsley, Kendra Sweet, Rami S. Komrokji, Paul B. Jacobsen

    Опубликовано 2012
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  17. 17
    Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes

    Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes по Asmita Mishra, Maria Corrales‐Yepez, Najla Al Ali, Mohamed A. Kharfan‐Dabaja, Eric Padron, Ling Zhang, Pearlie K. Epling‐Burnette, Javier Pinilla‐Ibarz, Jeffrey E. Lancet, Alan F. List, Rami S. Komrokji

    Опубликовано 2013
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  18. 18
    PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY

    PB1945: PATIENT PERSPECTIVES ON CLL TREATMENT SIDE EFFECTS: A SUB-ANALYSIS OF THE VOICE SURVEY по Constantine S. Tam, Javier Pinilla‐Ibarz, Volkan Karakuş, Miguel Arturo Pavlovsky, Stephan Stilgebauer, Martin Šimkovič, Ana Cristina Fenili, Miguel Augusto Miroli, Carolina García-Castillo, Kathryn Huntley, Catherine Moura, Fernando Piotrowski, Mervat Mattar

    Опубликовано 2023
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  19. 19
    Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

    Results of VOICE: a global survey of disease-specific knowledge and perspectives of real-world patients with CLL по Constantine S. Tam, Javier Pinilla‐Ibarz, Carolina García-Castillo, Ana Cristina Fenili, Kathryn Huntley, Volkan Karakuş, Mervat Mattar, Miguel Augusto Miroli, Catherine Moura, Miguel Arturo Pavlovsky, Fernando Piotrowski, Martin Šimkovič, Stephan Stilgenbauer

    Опубликовано 2023
    Полный текст Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:
  20. 20
    Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib

    Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib по Jorge E. Cortés, Andreas Hochhaus, Philipp D. le Coutre, Gianantonio Rosti, Javier Pinilla‐Ibarz, Elias Jabbour, Kathryn Gillis, Richard C. Woodman, Rick E. Blakesley, Francis J. Giles, Hagop M. Kantarjian, Michele Baccarani

    Опубликовано 2011
    Полный текст
    Artigo
    Добавить в Избранное
    Сохранить в:

Инструменты поиска: